GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » Cyclically Adjusted Price-to-FCF

Armata Pharmaceuticals (FRA:TG1N) Cyclically Adjusted Price-to-FCF : (As of Jun. 17, 2024)


View and export this data going back to . Start your Free Trial

What is Armata Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Armata Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Armata Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Armata Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Armata Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Armata Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Armata Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armata Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Armata Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Armata Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Armata Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.276/131.7762*131.7762
=-0.276

Current CPI (Mar. 2024) = 131.7762.

Armata Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -62.174 100.560 -81.475
201409 -47.667 100.428 -62.546
201412 -86.633 99.070 -115.234
201503 -72.067 99.621 -95.328
201506 -44.074 100.684 -57.685
201509 -55.429 100.392 -72.757
201512 -51.738 99.792 -68.320
201603 -68.357 100.470 -89.657
201606 -42.619 101.688 -55.229
201609 -35.646 101.861 -46.115
201612 -14.763 101.863 -19.098
201703 -25.750 102.862 -32.988
201706 -6.627 103.349 -8.450
201709 -0.830 104.136 -1.050
201712 -2.898 104.011 -3.672
201803 -3.019 105.290 -3.778
201806 -1.582 106.317 -1.961
201809 -0.317 106.507 -0.392
201812 -0.743 105.998 -0.924
201903 -0.495 107.251 -0.608
201906 -0.682 108.070 -0.832
201909 -0.428 108.329 -0.521
201912 -0.259 108.420 -0.315
202003 -0.375 108.902 -0.454
202006 -0.200 108.767 -0.242
202009 -0.183 109.815 -0.220
202012 -0.297 109.897 -0.356
202103 -0.237 111.754 -0.279
202106 -0.159 114.631 -0.183
202109 -0.190 115.734 -0.216
202112 -0.297 117.630 -0.333
202203 -0.117 121.301 -0.127
202206 -0.244 125.017 -0.257
202209 -0.326 125.227 -0.343
202212 -0.263 125.222 -0.277
202303 -0.507 127.348 -0.525
202306 -0.200 128.729 -0.205
202309 -0.343 129.860 -0.348
202312 -0.267 129.419 -0.272
202403 -0.276 131.776 -0.276

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Armata Pharmaceuticals  (FRA:TG1N) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Armata Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Armata Pharmaceuticals (FRA:TG1N) Business Description

Traded in Other Exchanges
Address
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Armata Pharmaceuticals (FRA:TG1N) Headlines

No Headlines